ABBV

AbbVie Inc. · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-20

Figures on this page computed 2026-11-08 12:24 UTC

Last close

288.24USD

Market data, 2026-11-05

Except where said otherwise: 10-K for 2025, filed 2026-02-20

122.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-20
The filing itself
16.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
The filing itself
6.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
The filing itself
29.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-K for 2025, filed 2026-02-20
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-02-20
- 10-Q for 2025, filed 2026-11-03
The filing itself
2.4%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- computed
- computed
- computed
- computed
- Computed from the filing for 2025, filed 2026-02-20

Price is the furthest below its sector's middle: 0.10 against 0.33 on the market's range.

Against its rival

lens 4 of 9

Measure by measure

behind on 4 of 5

Profit on each unit of sales6.9%17.4%Behind
Higher is better here.
Return on the capital it uses16.1%15.3%Ahead
Higher is better here.
Sales growth over five years6.0%17.2%Behind
Higher is better here.
Debt against equityn/a0.65n/a
Lower is better here.
Gross margin70.2%81.9%Behind
Higher is better here.
Price against earnings123x28.3xBehind
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against AstraZeneca PLC, ABBV is behind on 4 of 5 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-20

Profit on each unit of sales6.9%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Return on the capital it uses16.1%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Sales growth over five years6.0%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Gross margin70.2%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself
Price against earnings122.9x
Source
filed
Statement
income
Fiscal year
2025
Accession
0001551152-26-000008
Reported in
USD
The filing itself